Costs of traditional Chinese medicine treatment for inpatients with lung cancer in China: a national study

Table 3 Multiple regression analysis for total inpatient costs

Parameters	Coef.	P > z	95% Wald confidence interval
Parameters	Coef.	P > z	Lower	Upper
Use of TCM
TCM user	0.502	< 0.001	0.483	0.521
Length of stay	0.023	< 0.001	0.023	0.023
Age	−0.004	< 0.001	− 0.004	− 0.003
Sex
Male	0.006	0.412	−0.009	0.022
Insurance type
UEBMI	0.190	< 0.001	0.173	0.208
No of hospitalizations	0.046	< 0.001	0.040	0.051
Hospital type
Secondary hospital	0.233	< 0.001	0.196	0.271
Tertiary hospital	0.640	< 0.001	0.604	0.676
Region
Central	−0.234	< 0.001	− 0.253	− 0.215
West	−0.172	< 0.001	− 0.190	− 0.153
No of comorbidities	0.061	< 0.001	0.055	0.068
Year
2011	0.020	0.222	−0.012	0.052
2012	0.137	< 0.001	0.104	0.170
2013	0.276	< 0.001	0.245	0.307
2014	0.425	< 0.001	0.393	0.457
2015	0.419	< 0.001	0.388	0.451
2016	0.472	< 0.001	0.442	0.503
_Cons	7.993	< 0.001	7.930	8.056

R-square = 0.5419 and adjusted R-square = 0.5418 in a multiple linear regression model that was adjusted for the length of stay, age, sex, insurance type, number of hospitalizations, hospital level, region, number of comorbidities, and year of treatment. The baseline represents the inpatient cost for a female who did not use any TCM with Urban Resident Basic Medical Insurance admitted to a primary hospital in the eastern region without any comorbidity. TCM Traditional Chinese medicine, UEBMI Urban Employee Basic Medical Insurance scheme; URBMI Urban Resident Basic Medical Insurance scheme

ISSN: 2662-7671